Validation experiment designed to validate causal mechanisms targeting NTN1 in endometrial carcinoma mouse model. Primary outcome: tumor progression reduction
Preclinical evaluation of NP137, an anti-netrin-1 antibody, in a mouse model of endometrial carcinoma. The study assessed the therapeutic efficacy of netrin-1 blockade using NP137 antibody in reducing tumor progression. Mouse tumor gene profiling was performed to evaluate the mechanism of action, revealing that NP137 induced cell death and inhibited epithelial-to-mesenchymal transition (EMT) in addition to its anti-tumor effects. This experiment provided crucial preclinical evidence supporting the therapeutic potential of netrin-1 blockade in endometrial cancer.
Treatment with anti-netrin-1 antibody (NP137) and tumor gene profiling analysis
Reduced tumor progression, cell death induction, EMT inhibition
Significant reduction in tumor growth and EMT markers
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.